Compare NBBK & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBBK | LBRX |
|---|---|---|
| Founded | 1892 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.5M | 850.5M |
| IPO Year | 2023 | N/A |
| Metric | NBBK | LBRX |
|---|---|---|
| Price | $20.62 | $28.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $23.50 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 158.7K | 148.4K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 25.23 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.15 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $56.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.01 | $13.40 |
| 52 Week High | $22.86 | $33.47 |
| Indicator | NBBK | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 50.14 |
| Support Level | $20.17 | $26.44 |
| Resistance Level | $22.71 | $33.47 |
| Average True Range (ATR) | 0.40 | 1.59 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 92.09 | 60.99 |
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.